ACP
IMVT icon

Acuta Capital Partners’s Immunovant IMVT Stock Holding History

Acuta Capital Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-92,346
Closed -$2.98M – 37
2024
Q1 		$2.98M Sell
92,346
-27,143
-23% -$990K 1.94% 20
2023
Q4 		$5.03M Sell
119,489
-9,511
-7% -$350K 2.83% 16
2023
Q3 		$4.95M Sell
129,000
-12,755
-9% -$288K 3.32% 13
2023
Q2 		$2.69M Buy
+141,755
New +$2.64M 1.82% 20
2021
Q1 		– Sell
-283,500
Closed -$13.1M – 52
2020
Q4 		$13.1M Buy
283,500
+33,500
+13% +$1.55M 3.56% 9
2020
Q3 		$8.8M Sell
250,000
-100,000
-29% -$3.01M 2.39% 15
2020
Q2 		$8.52M Buy
+350,000
New +$7.5M 2.46% 15

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Acuta Capital Partners's IMVT Position: Q2 2024 in Review

Acuta Capital Partners sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 92,346 shares — an estimated $2.98M sold.

Acuta Capital Partners first reported a position in IMVT in Q2 2020 and held it in 7 quarters. The position peaked at $13.1M in Q4 2020. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Acuta Capital Partners reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 92,346 Immunovant shares in Q2 2024, an estimated $2.98M.
  • Acuta Capital Partners first reported a position in Immunovant in Q2 2020 and held it in 7 quarters.
  • Acuta Capital Partners's Immunovant position peaked at $13.1M in Q4 2020.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Acuta Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.